Skip to main content

Leader in Pulmonary Vascular Research Named New Editor-in-Chief of Circulation Journal

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Maron is a board-certified clinical cardiologist and distinguished researcher across the basic, translational, clinical and population health spectrum. He is recognized globally for mechanistic and clinical advances in pulmonary hypertension, right heart failure and cardiomyopathy, and his career bridges patient care, translational science and precision medicine, focused on pulmonary vascular disease, specifically how conditions that affect the blood vessels within the lungs impact the heart. Maron is senior associate dean for precision medicine, director of the Pulmonary Hypertension Center at the University of Maryland Medical Center, and the Melvin Sharovsky Professor of Medicine at the University of Maryland School of Medicine in Baltimore, as well as co-executive director of the University of Maryland Institute for Health Computing in Bethesda, Maryland. He previously held faculty appointments at Harvard Medical School and also served as a visiting professor of medicine at Imperial College London.

Maron succeeds Joseph A. Hill, M.D., FAHA, who has led Circulation since 2016, and Joseph Loscalzo, M.D., Ph.D., FAHA, who was Circulation’s editor-in-chief from 2004-2016. 

“Dr. Maron’s appointment as the next editor in chief of Circulation underscores the American Heart Association’s commitment to advancing transformative science shaping the future of cardiovascular medicine,” said Shelley Miyamoto, M.D., FAHA, chair of the Association’s Scientific Publishing Committee, which selected Dr. Maron to lead the editorial content of Circulation. Each of the Association’s scientific journals is editorially independent of one another, and they are also editorially independent of the Association in support of open dialogue and discourse, which are essential to the dynamic nature of scientific discovery and advances. “His vision, scientific breadth and dedication to robust research and innovation position Circulation for optimal success in its next chapter of influence and impact.”

“I am deeply honored to take on the remarkable role of leading Circulation,” said Maron. “I have pored over issues of Circulation since my early research career and marveled at the strength of the science and the rigorous standards. I am energized to forge a new path for the journal that strengthens and expands on the legacy and success of the editors before me, particularly Drs. Hill and Loscalzo, to whom I am grateful. Our mission is to reinvigorate the type of cardiovascular science and medicine published in Circulation, and fast track that information to our readers with additional transparency. A key goal is to share findings and perspectives from articles in Circulation in more engaging ways than ever before.”

Top new features of Circulation will include:

  • A new Clinician Lighthouse article: Expert-guided interpretation of diagnostic test results and patient management for practicing clinicians.
  • A new Clinician’s Corner: Clinician-oriented content that guides readers through key decision-making and real world clinical practice.
  • Key clinical trials and guideline manuscripts supported by perspective bundles that provide valuable context, details and insight.
  • Graphic abstracts for all research articles, central illustrations for most invited papers, and video commentaries for select manuscripts.
  • A streamlined and strengthened manuscript submission process with an accelerated and more transparent review timeline.
  • A new Patient’s Corner article: For the public/patient community, these articles are commissioned by the editors to thematically tie to and present key content. These articles may focus on a clinical trial manuscript, scientific statement, guideline or invited review article, for example.
  • Expanded, weekly eTOC (electronic Table of Contents) alerts including brief summaries of articles.  

Several additional upgrades for readers will roll-out in the first year.

Dr. Maron is joined by a new Circulation editorial team including:

In addition, 10 renowned specialists are now deputy editors for specific topic sections within the journal:

  • Fundamental Sciences - Joseph C. Wu, M.D., Ph.D., FAHA, from Stanford University in Stanford, California, and a past president of the Association (2023-2024);
  • Translational Science, Therapeutics and Physiology – Matthew L. Steinhauser, M.D., from the University of Pittsburgh in Pittsburgh;
  • Clinical Cardiology – Jennifer E. Ho, M.D., FAHA, from Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, and Ryan J. Tedford, M.D., FAHA, from The Medical University of South Carolina in Charleston, South Carolina;
  • Clinical Trials – Adrian F. Hernandez, M.D., M.H.S., FAHA, from Duke University School of Medicine in Durham, North Carolina, and P. Gabriel Steg, M.D., from Université de Paris-Cité in Paris, France;
  • Community Health – Tiffany Powell-Wiley, M.D., M.P.H., FAHA, from the National Institutes of Health in Bethesda, Maryland;
  • Population Health – Mercedes Carnethon, Ph.D., FAHA, from Northwestern University in Chicago;
  • Global Cardiovascular Health - Ana Mocumbi, M.D., Ph.D., from Universidade Eduardo Mondlane in Mozambique, Africa; and
  • AI for Process and Science – Thomas M. Maddox, M.D., M.Sc., FAHA, from Washington University School of Medicine in St. Louis, Missouri.

Circulation will also be supported by a team of 27 associate editors and guest editors.     

Maron earned a bachelor’s degree in psychology from Williams College and a doctor of medicine degree from Brown University School of Medicine, after beginning his medical studies at Tulane University School of Medicine. He completed his internal medicine training at Boston Medical Center and Boston University School of Medicine, followed by residency and a cardiovascular medicine fellowship at Brigham and Women’s Hospital and Harvard Medical School, with mentors Joseph Loscalzo, M.D., Ph.D., FAHA, and Jane A. Leopold, M.D., FAHA.  

Maron’s scientific impact includes co-authoring more than 260 scientific publications including peer-reviewed manuscripts, book chapters and other publications. He has served as the primary investigator for federally funded and collaborative research programs for more than two decades, discovered novel molecular mechanisms of vascular  fibrosis, led projects that clarified clinical risk and resilience in pulmonary hypertension, co-led a project using AI to automate clinical diagnosis, and helped advance the use of network medicine, big data and computational science to improve disease phenotyping and therapeutic discovery. Maron is a global leader in the basic mechanisms of pulmonary vascular remodeling and precision medicine, with six patents, inventions and copyrights confirmed or pending.   

He also brings substantial editorial and professional leadership experience, including prior reviewer and editor roles with multiple cardiovascular and respiratory journals, such as Circulation, The Lancet, The New England Journal of Medicine, PLOS Medicine, Science Translational Medicine, the Journal of Clinical Investigation, Annals of Internal Medicine, JAMA: Cardiology, the American Journal of Respiratory and Critical Care Medicine (Blue Journal), and JACC. Maron has also served in several volunteer leadership roles for the American Heart Association, the American College of Cardiology and the Pulmonary Vascular Research Institute.

Circulation is the flagship peer-reviewed journal of the American Heart portfolio of 14 peer-reviewed scientific journals: Stroke; HypertensionJournal of the American Heart AssociationArteriosclerosis, Thrombosis, and Vascular BiologyCirculation ResearchCirculation: Arrhythmia and ElectrophysiologyCirculation: Heart FailureCirculation: Cardiovascular ImagingCirculation: Cardiovascular Interventions; Circulation: Genomic and Precision Medicine; Circulation: Population Health and Outcomes; Stroke: Vascular and Interventional Neurology; and Annals of Internal Medicine: Clinical Cases. Each journal is editorially independent of one another, and they are also editorially independent of the Association in support of open dialogue and discourse, which are essential to the dynamic nature of scientific discovery and advances. Editors-in-chief are selected by the Association’s volunteer-led Scientific Publishing Committee, and each editor-in-chief assembles and manages the editorial board, vision and strategy for their journal. The Association is the publisher of the journals; however, the Association has no oversight on the scientific content published. Studies published in the American Heart Association’s scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability.

The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.

Additional Resources:

  • Photos available on the right column of news release.
  • Access the journal: Circulation
  • Follow American Heart Association news on X @HeartNews
  • Follow news from the American Heart Association’s flagship journal Circulation on X @CircAHA

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.

For Media Inquiries: 214-706-1173

Michelle Kirkwood: michelle.kirkwood@heart.org 

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.16
+1.49 (0.61%)
AAPL  312.66
+4.03 (1.31%)
AMD  552.05
+34.23 (6.61%)
BAC  59.90
+1.17 (1.99%)
GOOG  364.90
+8.72 (2.45%)
META  600.29
+17.39 (2.98%)
MSFT  386.74
-3.75 (-0.96%)
NVDA  195.55
+0.72 (0.37%)
ORCL  143.76
+3.49 (2.49%)
TSLA  419.77
+26.32 (6.69%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.